Expanding Diagnostic Approaches For Lynch Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$1,269,355.00
Summary
Currently, there are ~1,000 families who have attended Family Cancer Clinics across Australia who have the hallmarks of having Lynch syndrome, a hereditary bowel cancer syndrome, but who have no gene defect identified, i.e. their cancer is unexplained. Clinicians are challenged by these “Lynch-like” patients as their family cancer risk is unknown. Our research has identified new gene defects in Lynch-like patients. Our aim is to optimise clinical testing approaches for Lynch-like patients.
Muir Torre Syndrome: The Role Of IHC And Genotyping In Sebaceous Neoplasia To Facilitate Prevention Strategies In Colorectal And Endometrial Cancer
Funder
National Health and Medical Research Council
Funding Amount
$396,786.00
Summary
Sebaceous neoplasia (SN), may be an early warning sign for Lynch syndrome (LS), an inherited cancer predisposition caused by mutations in a group of genes. There are high lifetime risks of bowel and uterine cancer, for which there are effective risk management plans if the risk is known. Clinicians are challenged by the role of SN in identifying LS. At present, it is hard to differentiate. We aim to determine features to improve the diagnosis of LS carriers.
Overcoming Resistance To Anti-EGFR Antibody Therapy In Colorectal Cancer Using Novel Targeted PI3K And MEK Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$466,586.00
Summary
Cetuximab treatment is a standard of care for metastatic colorectal cancer, but patients with KRAS, BRAF, PIK3CA or PTEN gene mutated tumours show a lack of response. Newly developed targeted inhibitors against PI3K and MEK may overcome cetuximab resistance. We will perform preclinical studies in cell lines representing the range of mutated tumours found in patients to compare the efficacy of these novel treatments with cetuximab and to characterise the mechanisms underlying drug action.
Defining Iron And Haem-induced Pro-carcinogenic Pathways Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$566,277.00
Summary
Colorectal cancer is very common in Western society. Population studies have reported that high consumption iron-containing foods and red meat, the latter being a source of both haem and iron, are risk factors for colorectal cancer. This study will identify the levels of dietary haem and iron that promote colorectal cancer development. Also, it will determine the mechanisms and relative contribution of iron and haem to pro-carcinogenic pathways that result in colorectal cancer.
HEREDITARY ENDOCRINE CANCER: A MODEL BASED ON PHAEOCHROMOCYTOMA- PARAGANGLIOMA SYNDROMES
Funder
National Health and Medical Research Council
Funding Amount
$875,894.00
Summary
Phaeochromocytomas and paragangliomas are tumours remarkable for their very high heritability. They have a high burden of disease themselves, and their associated hereditary syndromes include risks for other malignancies. Our study will rationalize the pathological approach to diagnosing these hereditary syndromes, find new therapeutic targets for metastatic disease, and provide a template for other cancers with high heritable component.
Evaluation Of Blood-based Screening Tests For Colorectal Neoplasia; From Biomarker Candidates To Accurate And Acceptable Tests
Funder
National Health and Medical Research Council
Funding Amount
$767,382.00
Summary
Current bowel cancer screening tests require people to collect a stool sample. While able to be done at home, this creates certain inconveniences and has other barriers to its use including being distasteful to some. Also, even though stool tests are useful they are not as accurate as we would like. We have discovered a molecule in the blood of patients with bowel cancer that could, if configured as a screening test, serve to be of even greater accuracy and also be more acceptable to people.
The Role Of DNA Sensing In The Pathogenesis Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$633,704.00
Summary
Colorectal (bowel) cancer is a leading cause of death in Australia and worldwide. The ability of the body to detect DNA from damaged or dying cells in the gut is an important part of the healing process. This response also provides protection against colorectal cancer. In this project, we investigate how a DNA sensor prevents the development of intestinal tumours. This project will lead to new ways to fight cancer in humans.
Effectiveness And Cost-effectiveness Of Systematic Screening For Lynch Syndrome (LS) In Australia
Funder
National Health and Medical Research Council
Funding Amount
$485,762.00
Summary
Lynch syndrome (LS) is an inherited condition that puts people at an increased risk of developing a range of cancers. We will use a detailed simulation model to evaluate the potential health benefits of testing new cases of colorectal, endometrial and ovarian cancers for LS, and whether this would be cost-effective. The aim is to identify LS-related cancer cases, so family members can be offered LS testing, and individuals found to have LS can be offered close observation/preventative surgery.
A La CaRT: Australasian Laparoscopic Cancer Of The Rectum Trial. A Phase III Prospective Randomised Trial Comparing Laparoscopic-assisted Resection Versus Open Resection For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$599,054.00
Summary
The major treatment for rectal cancer is surgical removal of tumour with a large cut through the abdomen. There is a newer, less invasive procedure known as laparoscopic resection which enables the same surgery to be performed using a scope inserted in the abdomen and another smaller incision for removal of the tumour. This study is being conducted to determine whether the newer procedure is as safe and effective as the current procedure. Patients on the trial will be given either laparoscopi
Circulating Tumour DNA (ctDNA) To Guide Adjuvant Chemotherapy And Surveillance Strategies In Patients With Stage II Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,227,186.00
Summary
This study is attempting to demonstrate that an adjuvant therapy strategy based on ctDNA results will reduce the number of patients with stage II colon cancer receiving adjuvant chemotherapy without compromising recurrence free survival. Prospective multi-centre study enrolling 450 stage II colon cancer patients. Patients will be randomized 2:1 to be treated according to ctDNA results (Arm A, n = 300), or per standard clinical criteria (Arm B, n = 150).